Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
05 September 2023 - 10:00PM
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage
biotechnology company pioneering a new class of medicines that
treat serious diseases by correcting abnormal gene expression,
today announced management's participation in the following
investor conferences in September 2023. With an initial focus in
oncology, Foghorn’s Gene Traffic Control® platform and resulting
broad pipeline have the potential to transform the lives of people
suffering from a wide spectrum of diseases.
Wells Fargo 2023 Healthcare
Conference
- Management will participate in
one-on-one meetings on Friday, September 8, 2023, at the Encore
Boston Harbor, Everett, MA
Morgan Stanley
21st Annual Global Healthcare
Conference
- Fireside Chat: Monday, September
11, 2023, at 2:15 p.m. ET at the Sheraton New York, New York
City
- Foghorn Presenter: Adrian
Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast
here
- Management will also participate in
one-on-one meetings on Monday, September 11
H.C. Wainwright
25th Annual Global Investment
Conference
- Management will participate in
one-on-one meetings on Tuesday, September 12, 2023, at the Lotte
New York Palace Hotel, New York City
A webcast of the fireside chat can also be
accessed under “Events & Presentations” in the Investors
section of Foghorn’s website, www.foghorntx.com, and will be
available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel
class of medicines targeting genetically determined dependencies
within the chromatin regulatory system. Through its proprietary
scalable Gene Traffic Control® platform, Foghorn is
systematically studying, identifying and validating potential drug
targets within the chromatin regulatory system. The Company is
developing multiple product candidates in oncology. Visit our
website at www.foghorntx.com for more information about the
company, and follow us on X (formerly Twitter) and LinkedIn.
Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and
Investors)bstrain@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc.
(Media)khellsvik@foghorntx.com
Foghorn Therapeutics (NASDAQ:FHTX)
Historical Stock Chart
From Apr 2024 to May 2024
Foghorn Therapeutics (NASDAQ:FHTX)
Historical Stock Chart
From May 2023 to May 2024